156 related articles for article (PubMed ID: 38171144)
1. Impact of Hyperglycemia on Complication and Mortality after Transarterial Chemoembolization for Hepatocellular Carcinoma.
Moon SJ; Ahn CH; Lee YB; Cho YM
Diabetes Metab J; 2024 Mar; 48(2):302-311. PubMed ID: 38171144
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.
Zhou C; Wang R; Ding Y; Du L; Hou C; Lu D; Hao L; Lv W
Int J Clin Exp Pathol; 2014; 7(5):2579-86. PubMed ID: 24966972
[TBL] [Abstract][Full Text] [Related]
4. Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Sohn W; Ham CB; Kim NH; Kim HJ; Cho YK; Jeon WK; Kim BI
PLoS One; 2020; 15(12):e0243780. PubMed ID: 33315944
[TBL] [Abstract][Full Text] [Related]
5. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
6. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
7. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.
Lee BC; Liu KL; Lin CL; Kao CH
Eur Radiol; 2017 Nov; 27(11):4482-4489. PubMed ID: 28593432
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
[TBL] [Abstract][Full Text] [Related]
10. [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
Jang BK; Lee SH; Chung WJ; Park KS; Cho KB; Hwang JS; Kim YH; Choi JS; Kwon JH
Korean J Hepatol; 2008 Jun; 14(2):168-77. PubMed ID: 18617764
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
[TBL] [Abstract][Full Text] [Related]
14. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency.
Hsu CY; Huang YH; Su CW; Chiang JH; Lin HC; Lee PC; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2010 Sep; 44(8):e171-7. PubMed ID: 20048685
[TBL] [Abstract][Full Text] [Related]
16. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
17. Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: a propensity score matching analysis.
Chu HH; Gwon DI; Kim GH; Kim JH; Ko GY; Shin JH; Ko HK; Yoon HK
Eur Radiol; 2023 Apr; 33(4):2655-2664. PubMed ID: 36472699
[TBL] [Abstract][Full Text] [Related]
18. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study.
Boteon APCDS; Boteon YL; Vinuela EF; Derosas C; Mergental H; Isaac JR; Muiesan P; Mehzard H; Ma YT; Shah T; Mirza DF; Perera MTPR
Clin Transplant; 2018 May; 32(5):e13255. PubMed ID: 29637619
[TBL] [Abstract][Full Text] [Related]
19. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma].
Schneeweiß S; Horger M; Ketelsen D; Ioanoviciu SD
Rofo; 2015 Feb; 187(2):79-82. PubMed ID: 25629286
[No Abstract] [Full Text] [Related]
20. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
